Matan C. Dabora, MD, MBA; Namrata Turaga, MD, MBA; Kevin A. Schulman, MD
free access
JAMA. 2017;318(1):21-22. doi:10.1001/jama.2017.5607
This Viewpoint identifies stakeholders in the financing and distribution of pharmaceuticals in the United States and describes their flow from manufacturers through distributors, managers, and retailers to patients.
Kasia J. Lipska, MD, MHS; Irl B. Hirsch, MD; Matthew C. Riddle, MD
JAMA. 2017;318(1):23-24. doi:10.1001/jama.2017.6939
This Viewpoint suggests that clinicians prescribe human insulin products as a more-affordable option over insulin analogues and explains dosing options.
Samuel T. Edwards, MD, MPH; David A. Dorr, MD, MS; Bruce E. Landon, MD, MBA, MSc
JAMA. 2017;318(1):25-26. doi:10.1001/jama.2017.6953
This Viewpoint proposes that integration of patient goals, optimization of chronic disease management, and central record-keeping are essential if personalized care planning is to improve primary care and patient outcomes rather than simply burden primary care practices.
Muin J. Khoury, MD, PhD
JAMA. 2017;318(1):27-28. doi:10.1001/jama.2017.6315
This Viewpoint discusses the 2017 National Academies of Sciences, Engineering, and Medicine (NASEM) report on improving the system of evaluation of genetic testing so that implementation of genomic medicine in clinical settings can be evidence-based.